SCHEMBL13386254

SCHEMBL13386254

CCc1cc(N2CCOCC2)cc2c1Nc1c(CC)cc(N3CCS(=O)(=O)CC3)cc1S2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
ALDH1A1 P00352 6/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PIK3C3 Q8NEB9 3/20 0.37
SMN1; SMN2 Q16637 4/20 0.33
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
PKM P14618 1/20 0.33
GAA P10253 3/20 0.33
IDE P14735 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13386157 0.94 ALDH1A1 (0.38) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13386162 0.88 MAPT (0.44) MAPTALDH1A1MEN1KMT2AKDM4E
Iodide SCHEMBL13386326 0.86 MAPT (0.44) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13737166 0.85 MEN1 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13386124 0.84 MAPT (0.39) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13386320 0.81 LMNA (0.40) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13386113 0.81 MAPT (0.44) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2594059 0.81 MEN1 (0.39) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL16004713 0.80 MAPT (0.39) MAPTALDH1A1MEN1KMT2AKDM4E
Iodide SCHEMBL13386095 0.79 MAPT (0.38) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699241-B1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC (US) 2016-07-27 EP disclosed
US-8828986-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-09-09 US disclosed
EP-2699241-A1 ANTIVIRAL COMPOUNDS Prosetta Antiviral Inc. (US) 2014-02-26 EP disclosed
WO-2012145567-A1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC. (US) 2012-10-26 WO disclosed
US-20120270854-A1 Antiviral Compounds PROSETTA ANTIVIRAL INC. (US) 2012-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270854-A1 Antiviral Compounds HAVCR2, MAVS, EIF2AK2 MAPT 1569/4885ALDH1A1 1002/4885MEN1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.